Alzheimer disease (AD) is defined by progressive impairments in memory and cognition and by the presence of extracellular neuritic plaques and intracellular neurofibrillary tangles. However, oxidative stress and impaired mitochondrial function always accompany AD. Mitochondria are a major site of production of free radicals [ie, reactive oxygen species (ROS)] and primary targets of ROS. ROS are cytotoxic, and evidence of ROS-induced damage to cell membranes, proteins, and DNA in AD is overwhelming. Nevertheless, therapies based on antioxidants have been disappointing. Thus, alternative strategies are necessary. ROS also act as signaling molecules including for transcription. Thus, chronic exposure to ROS in AD could activate cascades of genes. Although initially protective, prolonged activation may be damaging. Thus, therapeutic approaches based on modulation of these gene cascades may lead to effective therapies. Genes involved in several pathways including antioxidant defense, detoxification, inflammation, etc, are induced in response to oxidative stress and in AD. However, genes that are associated with energy metabolism, which is necessary for normal brain function, are mostly down-regulated. Redox-sensitive transcription factors such as activator protein-1, nuclear factor-kB, specificity protein-1, and hypoxia-inducible factor are important in redox-dependent gene regulation. Peroxisome proliferators-activated receptor-g coactivator (PGC-1a) is a coactivator of several transcription factors and is a potent stimulator of mitochondrial biogenesis and respiration. Down-regulated expression of PGC-1a has been implicated in Huntington disease and in several Huntington disease animal models. PGC-1a role in regulation of ROS metabolism makes it a potential candidate player between ROS, mitochondria, and neurodegenerative diseases. This review summarizes the current progress on how oxidative stress regulates the expression of genes that might contribute to AD pathophysiology and the implications of the transcriptional modifications for AD. Finally, potential therapeutic strategies based on the updated understandings of redox state-dependent gene regulation in AD are proposed to overcome the lack of efficacy of antioxidant therapies.
OXIDATIVE STRESS AND ALZHEIMER DISEASE
Alzheimer disease (AD) is defined by progressive impairments in memory and cognition and by the presence of extracellular neuritic plaques and intracellular neurofibrillary tangles (NFTs). Amyloid-b peptide (Ab) is the major component of the plaque, whereas the tangles are composed of hyperphosphorylated tau proteins. As these 3 features define AD, any hypothesis about AD must explain their presence. Nevertheless, formation of plaques and tangles may be end point lesions and an adaptive response rather than deleterious response. Many other changes occur in AD brains, including nerve cell death, synaptic loss, proliferation of reactive astrocytes, and microglial activation. All of these may reflect some other initiating factors. [1] [2] [3] [4] [5] These same initial events may cause the cascades of gene responses that have been identified in AD. Although the genetic responses may be beneficial in early stages, they may be harmful in the long term (eg, they can further diminish metabolism). Defining changes that initiate AD and lead to cascades of genetic responses and also the formation of plaques and tangles would provide attractive therapeutic targets.
Overwhelming evidence suggests that oxidative stress increases with age through variations in reactive oxygen species (ROS) generation, ROS elimination, or both. 6 Studies have shown that ROS levels are increased with age in major organs including brain. 7, 8 Mitochondria are the major sites for ROS generation. Mitochondrial DNA (mtDNA) is situated very close to the site of mitochondrial ROS production. Mutations in mtDNA occur with aging especially in postmitotic tissues such as brain and increase to high levels in old people. [9] [10] [11] Increased mtDNA mutations have been linked directly to an accelerated rate of aging in mice. 12 These alterations in mtDNA can impair mitochondrial respiration and lead to enhanced ROS generation. 13 In addition, free radicalscavenging enzymes are also altered with aging. For example, the activity of Cu/Zn superoxide dismutase (Cu/ZnSOD) is decreased in aged rat brains 14 and in brains from AD patients. 15 Thus, the concurrent agerelated changes in ROS generation and elimination result in the elevation of oxidative stress in aging tissues. Although overwhelming evidence links increased mtDNA mutations directly with aging, studies on postmortem brain have failed to find consistent mutations in AD mtDNA beyond those associated with aging. 16 A cybrid model of AD has been developed by fusion of the membranes of platelets from AD patients to human neural host cells that are devoid of mitochondrial genes. 17, 18 AD cybrids replicate multiple abnormalities found in AD brain, suggesting that alterations in mtDNA may contribute to pathogenesis and progression of AD. 16 Direct expression of mtDNA mutations that are either linked with or beyond aging in isolated heterogenous AD neurons will provide a definitive test of whether a specific mutation in mtDNA is pathogenic to AD.
Accumulating evidence suggests that oxidative stress is an early event in AD. Oxidative stress occurs when the oxidative balance is disturbed, that is, excessive production of ROS to cellular antioxidant defenses. The brain is particularly vulnerable to oxidative stress because it is rich in unsaturated fatty acids, it consumes much more oxygen per gram compared with other tissue and it has less antioxidant enzymes than other organs. [19] [20] [21] The early involvement of oxidative stress in AD is demonstrated by oxidative modifications of lipids, [22] [23] [24] proteins, [25] [26] [27] and nuclei acids 28, 29 in brains from AD patients, and also in cellular and animal models of AD. Oxidative stress-modified molecules are detected not only in extracellular plaques, but also within cells. For example, elevated 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation, is found in amyloid-b peptide (Ab) plaques associated with AD. 30 4-HNE-pyrrole immunoreactivity also occurs in neurons with or without NFTs in brains of AD patients. 24 Oxidized RNA nucleoside 8-hydroxyguanosine is significantly increased in neurons from the frontal cortex of familial AD (FAD) with a mutation in presenilin-1 (PS-1) or amyloid-b protein precursor (AbPP) gene. 28 Moreover, the activity of a mitochondrial enzyme a-ketoglutarate dehydrogenase complex (KGDHC) is reduced in brains of AD patients. KGDHC is sensitive to various oxidants whether they are added to cells or generated internally in cells. 31 Biomolecules modified by oxidative stress exist in neurons with or without NFTs and plaques suggests that oxidative stress precedes the formation of AD pathologies and is a very early contributor to the disease. In mouse models of plaque formation, evidence of oxidative stress is apparent in urine before plaques are formed in brain. 32, 33 Oxidative stress occurs before Ab deposition in a Tg2576 APP transgenic mice model. 33, 34 Evidence of oxidative stress also occurs in urine of AD patients. 22, 32 Moreover, increased levels of oxidative damage occur in individuals with mild cognitive impairment (MCI), which is often believed to be one of the earliest stages of AD. 35 For example, the levels of HNE are elevated in MCI hippocampus and inferior parietal lobules compared with those of control brain. 36 Glial heme oxygenase-1 expression in the MCI temporal cortex and hippocampus is also significantly greater than in the nondemented group. 37 Together, these data support oxidative stress serving as an early event that leads to the development of cognitive disturbances and pathologic features observed in AD.
An understanding of how ROS may lead to AD requires an understanding of the different kinds of radicals and their origin ( Table 1 ) (for reviews Refs. [38] [39] [40] . Superoxide is a normal product of metabolism that is short lived and can serve as a signaling molecule within molecules and perhaps between pathways. The primary ROS generated in mitochondria is superoxide (O 2 À ), which is then converted to H 2 O 2 by spontaneous dismutation or by SOD. H 2 O 2 can also be further transformed to OH in the presence of metal ions by Fenton chemistry. NO serves as signaling molecule, but its reaction with superoxide produces peroxynitrite, which is very damaging to multiple macromolecules. Superoxide reacts with unsaturated lipids to produce lipid hydroperoxyl radicals and reactive aldehydes.
The origin of these ROS is also critical to our understanding of how they might alter gene transcription. There are several major sites of ROS production in the cells, including mitochondria. The major source of radicals during unstressed conditions is not clear, but during pathologic conditions, mitochondria seem to be a major source. For example, monoamine oxidase is located on the mitochondrial outer membrane, and participates in the degradation of neurotransmitters, which leads to generation of H 2 O 2 . 41 The up-regulation of monoamine oxidase, and a consequent increase in H 2 O 2 generation, has been implicated in several pathologic conditions including Parkinson disease. 42 Arachidonate oxidation leads to isoprostane formation, which is an early change in AD and mouse models of plaque formation. 33, 43 Xanthine oxidase, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, P450 enzymes, and nitric oxide synthase all contribute to ROS formation. The relative contribution of these various sources is difficult to evaluate, and could all clearly contribute to AD through altered signaling pathways.
THE RELATION OF IMPAIRED ENERGY METABOLISM IN AD TO OXIDATIVE STRESS
The brain depends heavily on glucose metabolism, which is diminished in AD. Although not a part of the formal definition, AD does not occur without a reduction in cerebral blood flow and oxygen utilization. In rare 44, 45 Similarly, MCI patients, who will develop AD, have diminished metabolism. [46] [47] [48] Production of ROS is a normal part of the electron transport chain, and impairment of the electron transport promotes free radical generation. For example, cytochrome oxidase (complex IV of the electron transport chain) is reduced in brains of AD patients. [49] [50] [51] Inhibition of this enzyme increases the production of ROS. [52] [53] [54] Furthermore, ROS production is also increased under hypoxia condition because there is no acceptor for the electrons available. These oxidants damage molecules but also serve as signaling molecules. In a chronic disease such as AD, it seems likely that free radicals are produced continuously. This would also promote changes in gene regulation. In a simplistic way, brain metabolism can be divided into 4 distinct pathways: glycolysis, the pentose shunt, the tricarboxylic acid (TCA) cycle, and the electron transport chain (Figs. 1, 2). As the brain is exposed to oxidative stress or increased production of ROS, these pathways can be altered by direct modification of the enzymes or by changes at the level of gene expression. The pentose shunt and glycolysis do not use oxygen so that they do not produce ROS. Nevertheless, they are involved in ROS production. The pentose shunt produces NADPH. NADPH oxidase is activated during respiratory burst. It generates superoxide by transferring electrons from NADPH inside the cell across the membrane and coupling these to molecular oxygen to produce the superoxide. In addition, ROS can act directly on these proteins. For example, oxidants modify glyceraldehyde-3phosphate dehydrogenase in a way that promotes its migration to the nucleus. Alternatively, oxidants modify patterns of gene expression of these proteins through modification of transcription factors as described in more detail below.
Glycolysis and its Alterations With AD
Glycolysis converts glucose to pyruvate and lactate with the production of relatively small amounts of NADH and adenosine triphosphate (ATP) ( Fig. 1 ). Acceleration of glycolysis occurs when mitochondrial function is impaired. Indeed, acceleration of glycolysis can keep cells from dying when mitochondrial function is impaired. The ROS signals that are produced in mitochondria serve this function by activating expression of glycolytic genes and inactivating the downstream pathways, including the TCA cycle. 55 Mitochondrial glycerophosphate dehydrogenase (mGPDH) participates in the reoxidation of cytosolic NADH by delivering reducing equivalents from this molecule into the electron transport chain, thus sustaining glycolysis. mGPDH is involved in maintaining a high rate of glycolysis and is an important site of electron leakage leading to ROS production in prostate cancer cell lines. 56 Whether mGPDH is a site for ROS generation in neurons or other cell types is unknown.
Reported changes in glycolytic enzymes in AD are controversial. Although early findings suggested large decreases, more recent reports show only moderate changes or increases. Measurements using optimal techniques reveal consistently higher activities of hexokinase, lactate dehydrogenase, and pyruvate kinase and consistently lower activities of glucose-6-phosphate dehydrogenase. 57, 58 Phosphofructokinase is significantly increased in frontal and temporal cortex and unchanged in the other brain areas studied when compared with control brains. 59 Glyceraldehyde-3-phosphate dehydrogenase is increased by 74%. 58 The increased glycolysis may be an adaptive response. Clonal nerve cell lines and primary cortical neurons that are resistant to Ab toxicity have enhanced flux of glucose through glycolysis. 58 
Pentose Shunt and its Alterations in AD
The pentose shunt (hexose monophosphate shunt) is responsible for producing NADPH, which is critical in the formation of glutathione and NO (Fig. 1 ). The activities of transketolase are reduced more than 45% in AD brains compared with controls. Small but statistically significant abnormalities of transketolase also occur in red blood cells and cultured fibroblasts from AD patients. 60 Clonal nerve cell lines and primary cortical neurons that are resistant to Ab toxicity have an enhanced flux of glucose through the hexose monophosphate shunt, which suggests this flux is protective. 58 
TCA Cycle and it Alterations in AD
The TCA cycle consists of 8 enzymes that are encoded by 15 genes (Fig. 1 ). The regulation of the transcription of these genes has not been studied very extensively. The TCA cycle is the major producer of reducing equivalents in the form of NADH and FADH. These reducing equivalents are then used by the electron transport chain to produce ATP. As described in more detail below, relatively recent studies also indicate that some enzymes of the TCA cycle are major producers of H 2 O 2 under reducing conditions. 61, 62 Altered activities of the TCA cycle enzymes are likely associated with AD-related changes in metabolism. It has been known since 1988 60 that the activities of the KGDHC are diminished in multiple brain areas and this has been reproduced multiple times. Diminished KGDHC activity also occurs in cells treated with oxidants 63 and thiamine deficient mice, an animal model with mild oxidative stress. 64, 65 More recent studies have shown that the dehydrogenases of the TCA cycle that are also decarboxylases are all diminished in AD brain. On the other hand, the enzymes that serve only as dehydrogenases are increased. The reduction in the activity of these enzymes is highly correlated to a clinical dementia rating score before the patients die. 66 Whether the changes occur at the gene level or whether posttranslational modifications are responsible is unknown. Further studies using cellular or animal models to address the mechanisms underlying these changes in relation to oxidative stress are necessary.
Electron Transport Chain and its Alterations in AD
The electron transport chain converts the reducing equivalents from other aspects of metabolism to a hydrogen ion gradient. The final step, ATP synthase, converts the H + gradient into ATP ( Fig. 2 ) (For detailed references see Ref. 67 ). Complex I is composed of 14 central subunits that contain all the known redox cofactors of the complex. In mammals, these subunits are encoded by the mtDNA. Mammalian complex I contains up to 32 additional subunits that are all encoded by nuclear genes. Complex II (ie, succinate dehydrogenase of the TCA cycle) contains 4 subunits and is bound to the inner mitochondrial membrane and participates in the citric acid cycle and the respiratory chain. An electron transferring flavoprotein accepts electrons from different substrate dehydrogenases and transfers them to the innermembrane bound ubiquinone oxidoreductase. The electron transfer protein is a heterodimeric complex, which consists of 2 subunits, a and b that are both nuclear encoded. Complex III consists of a homodimer of 2 bc 1 complex monomers. The mammalian bc 1 complex is composed of 11 subunits. Cytochrome b is encoded by the mitochondrial genome, and all of the other subunits are encoded by nuclear genes. Complex IV includes 3 conserved subunits I, II, and III, representing the minimal core of the enzyme. The mammalian aa 3 cytochrome c oxidase has 3 conserved subunits encoded by the mtDNA and 10 nuclear encoded subunits.
A key feature of cellular respiration is the regulation of the functional capacity of respiratory chain complexes at the level of gene expression, 68 posttranslational processing, 69 membrane traffic, 70 membrane assembly, 71 and flux control processes. 72 There is also cross talk at the gene level between the TCA cycle and the proteins of the electron transport. A novel mRNA that is transcribed starting from intron 7 in the DLST gene (encoding E2k protein of KGDHC of the TCA cycle) helps to regulate genes involved in electron transport. The truncated gene product (designated MIRTD) is localized to the intermembrane space of mitochondria. Cells deficient in this protein exhibit a marked decrease in the amounts of subunits of complexes I and IV of the mitochondrial respiratory chain, resulting in a decline of activity. The novel mRNA level in the brain of AD patients was significantly lower than that of controls. Thus, the DLST gene is bifunctional and MIRTD transcribed from the gene contributes to the biogenesis of the mitochondrial respiratory complexes. 73 Many groups have tested for changes in oxidative phosphorylation (OXPHOS) in AD, and the results are equivocal. The activities of mitochondrial respiratory chain enzyme complexes I+III, complexes II+III, complex IV (cytochrome c oxidase, COX), succinate dehydrogenase, and citrate synthase in the frontal cortex, temporal cortex, hippocampus, and cerebellum have all been measured. The major finding is a decrease in COX activity in AD temporal cortex and hippocampus. The defect is confined to selected brain regions, suggesting anatomic specificity that is secondary to neurodegeneration. 74 Others found that compared with controls, COX activity is decreased significantly in platelets ( À 30%) and hippocampus ( À 35% to À 40%), but not in motor cortex from the AD patients. F1F0-ATPase is not altered in the same samples. 75 Studies of mitochondria from patients with AD reveal a generalized depression of activity of all electron transport chain complexes, but the depression is most marked in COX activity (P<0.001). Concentrations of cytochromes b, c1, and aa3 are similar in AD and controls. 76 However, others find complex III core protein 1 is significantly reduced in the temporal cortex of AD patients. 77 Kish and colleagues 78 find mean COX activity in AD brain is reduced in frontal ( À 26%), temporal ( À 17%;), and parietal ( À 16%) cortices. In occipital cortex and putamen, mean COX levels are normal, whereas in hippocampus, COX activity, on average, is not significantly elevated (20%). The reduction of COX activity, which is tightly coupled to neuronal metabolic activity, could be explained by hypofunction of neurons, neuronal, or mitochondrial loss, or possibly by a more primary, but region-specific, defect in the enzyme itself. 78 This section briefly summarized the association of oxidative stress with diminished energy metabolism in AD and the possible modifications of metabolic enzymes by oxidants. Although oxidative stress-induced alteration in mitochondria function seems to contribute to ADrelated changes in metabolism, decreased metabolism in AD may reflect decreased synaptic activity. 79 Changes in synaptic structure and function in early stages of AD may lead to potentially reversible down-regulation of OXPHOS within neuronal mitochondria. 79 Although decreased demand may underlie changes in OXPHOS enzymes, there is no evidence that the levels of TCA cycle enzymes are regulated by neuronal activity. This supports the suggestion that inactivation of these enzymes could underlie the decline in metabolic function which would lead to decline in mental function.
MAJOR SITES OF ROS PRODUCTION Electron Transport Chain
The metabolic sites for production of ROS in cells have been reviewed extensively recently 38, 80 and are shown in Figures 1 and 2 . Traditionally, the primary source of ROS in the mitochondria is the electron transport chain. ROS can be produced at complex I, complex II, and complex III. Impairment of the electron transport chain beyond these reactions increases ROS formation. For example, azide blocks the final step of the electron transport and increases detectable ROS. 52 The main source of O 2 À from the electron transport is believed to be the ubisemiquinone radical (QH ), formed at the complex III Q O site, facing the intermembrane space. [81] [82] [83] [84] A build-up of the mitochondrial membrane potential can increase ROS, whereas dissipation of the mitochondrial membrane potential can decrease ROS. 85, 86 Dehydrogenases Recent studies suggest that several dehydrogenases in the TCA cycle may generate ROS. Most notably, KGDH and pyruvate dehydrogenase (PDH) have been identified as sources of ROS. 61, 62, 87 Both of these enzymes contain miniature electron transport chains, including a-lipoic acid, NADH, and flavin binding sites. The precise site within these chains where electrons may interact with O 2 to generate ROS is not known. Interestingly, such inhibition of the TCA cycle dehydrogenases would slow down the entry of electrons into the respiratory chain, by decreasing the generation of NADH, and this in turn would slow down ROS generation by complexes I and III. Such a feedback loop would function as a safety valve, to prevent overproduction of ROS by the respiratory chain. 88 This seems to have biologic importance in aging. Replicative life span in Saccharomyces cerevisiae is increased by glucose limitation [calorie restriction (CR)] and increased NAD + . Strains defective in NAD + synthesis and salvage pathways exhibit decreased oxygen consumption and increased mitochondrial H 2 O 2 release, and this is reversed by CR. These mutant strains live shorter and are rescued by CR. Furthermore, the changes in mitochondrial H 2 O 2 release alter cellular redox state, as shown by reversal of changes in total, oxidized, and reduced glutathione. Deletion of the dihydrolipoyl-dehydrogenases gene prevents oxidative stress in the mutants.
The results indicate that matrix-soluble dihydrolipoyldehydrogenases are an important source of CR-preventable mitochondrial ROS. Furthermore, pyruvate and a-ketoglutarate, substrates for dihydrolipoyl-dehydrogenase-containing enzymes, promote pronounced reactive oxygen release in permeabilized wild-type mitochondria. Altogether, these results substantiate the concept that mitochondrial ROS can be limited by caloric restriction and play an important role in S. cerevisiae senescence. Furthermore, these findings suggest that dihydrolipoyldehydrogenase is likely to be an important and novel source of ROS leading to life span limitation. 89 
Amyloid-b Peptide
Although amyloid-b peptide (Ab) is the neurotoxic species implicated in the pathogenesis of AD, mechanisms through which intracellular Ab impairs cellular properties and produces neuronal dysfunction remain to be clarified. Considerable evidence exists that Ab can increase the production of free radicals and this radical may be generated by the Ab molecule. [90] [91] [92] Intracellular Ab is present in mitochondria from brains of transgenic mice with targeted neuronal overexpression of mutant human amyloid precursor protein (APP) and AD patients. Ab progressively accumulates in mitochondria and is associated with diminished enzymatic activity of respiratory chain complexes (III and IV) and a reduction in the rate of oxygen consumption. Importantly, mitochondriaassociated Ab, principally Ab42, was detected as early as 4 months, before extensive extracellular Ab deposits. 93 Moreover, activation of NADPH oxidase by Ab42 results in ROS production in rat primary culture of microglial cells. 94, 95 Microglial NADPH Oxidase Several lines of evidence suggest that one of the source of ROS is the microglial NADPH oxidase. 94, [96] [97] [98] [99] [100] The neuropathologic hallmarks of AD are the NFTs and the senile plaques. The latter are surrounded by activated microglia. Exposure of microglial cells to inflammatory stimuli activates the microglial NADPH oxidase that leads to generation of O 2 À . Generation of O 2 À will further enhance the production of more potent free radicals such as peroxynitrite. The formation of peroxynitrite induces protein oxidation, lipid peroxidation, and nucleic acid oxidation. 100 
RELATION OF OXIDATIVE STRESS AND NEUROPATHOLOGY
Increases in oxidative stress can lead to the classic neuropathology. 101 Impairing oxidation can promote the formation of amyloidogic fibrils of Ab peptide. [102] [103] [104] [105] [106] Further, oxidative stress and interruption of metabolism can promote hyperphosphorylation of tau in a manner that is reminiscent of tangles. 107, 108 If enough free radicals are generated to cause these pathologic changes, it seems likely that these same free radicals could interact with gene expression.
OXIDATIVE STRESS AND ALTERED GENE EXPRESSION IN AD
Oxidative stress has been recently recognized to play an important role in signal transduction and transcription of specific genes through the activation of redox-sensitive transcription factors. Genes involved in several pathways that are associated with AD pathology are outlined and their intimate relations to oxidative stress are discussed.
Stress Response and Antioxidant Genes
As described previously, overwhelming evidence suggests that oxidative stress is an early event in AD pathology and this is reflected at the gene level. Genes related to oxidative stress and antioxidant pathways are generally induced in AD ( Table 2 ). For example, heme oxygenase-1 is a 32-kd stress protein that degrades prooxidant heme to antioxidant biliverdin, free iron, and carbon monoxide. 129 The induction of both mRNA and protein of heme oxygenase-1 in cerebral cortex and vessels of AD suggests an antioxidant defense in AD that is mediated at the level of transcription. [109] [110] [111] [112] Expression of genes for antioxidant enzymes are also elevated in AD. For example, the gene expressions of Mn-SOD, N/A indicates regulation of a particular gene in cell/animal models of AD by oxidative stress is unknown; +, up-regulated; À , down-regulated;+/ À , up-regulation in moderate AD followed by down-regulation in severe AD. Cu, Zn-SOD, catalase (CAT), glutathione peroxidase (GSH-Px), and glutathione reductase (GSSG-R) are induced in brains from AD patients. 115 These findings provide direct evidence that oxidative stress in AD increases relevant gene expression.
Inflammatory Genes
Oxidative stress also leads to up-regulation of inflammatory genes, which have been implicated in AD ( Table 2) . A DNA microarray study of hippocampal gene expression in control and AD individuals with varying severity reveals involvement of inflammatory processes in AD pathology. 119 For example, gene expression of several inflammatory markers such as interferon-g (IFN-g), interleukin family (IL-6, 18), IL receptors, and inducible nitric oxide synthase (iNOS) is up-regulated in incipient AD. 119, 121 ROS can stimulate production of these genes. Hydrogen peroxide synchronously promotes phosphoactivation of several distinct protein kinase cascades, including p38-mitogen activated protein kinase (p38-MAPK) and c-Jun amino terminal kinase (JNK) in primary rat astrocytes. 130, 131 p38-MAPK regulates expression of inflammatory cytokines, including IL-1b, 131 iNOS, and tumor necrosis factor-a. 132, 133 In AD, increased levels of phosphoactivated p38-MAPK are detected in neurons with plaques and NFTs. 134 Elevated gene expression of MAPK family such as MAPK1 and MAPK12 also occur in brains of AD patients. 119 Thus, oxidative stress induces inflammatory gene expression that is associated with AD possibly through MAPK pathways.
Genes of the TCA Cycle
Mitochondrial dysfunction is a major cause of oxidative stress in AD. Increased oxidative stress, in turn, disrupts mitochondrial function. Several lines of evidence suggest that altered gene expression of mitochondrial enzymes may account for early mitochondrial dysfunction and oxidative stress in AD. Several genes involved in mitochondrial TCA cycle are altered in autopsy brains of AD patients as determined by DNA array and/or real-time reverse-transcription polymerase chain reaction (Table 2 ). Decreased gene expression of mitochondrial aconitase, succinyl-CoA synthetase b, fumarase and mitochondrial malate dehydrogenase occurs in hippocampal samples from autopsy AD brains in 2 independent studies. 119, 123 Interestingly, oxoglutarate dehydrogenase, the gene encoding one of the subunits of KGDHC, shows increased and decreased gene expression in moderate and severe AD patients, respectively. 119 KGDHC can be the rate-limiting enzyme of the TCA cycle. These findings suggest that altered expression of the TCA cycle genes in AD may represent an early event that will later lead to mitochondrial dysfunction and further promote oxidative stress. Whether oxidative stress is a direct inducer of altered gene expression is not clear.
Genes of Electron Transport Chain
Genes associated with OXPHOS are implicated in AD ( Table 2) . Decreased mRNA levels of the mitochondrial-encoded cytochrome oxidase (COX) subunits I, II, and III occur in brains of AD patients. 49, 123, 125 Reduced expression of nuclear encoded subunits of mitochondrial enzymes of OXPHOS, including subunit IV of COX and the b-subunit of the F1F0-ATP synthase is also observed in vulnerable areas of AD brains. 50, 123 These data suggest that the decrease in mRNA involved in OXPHOS in affected brain regions may contribute to reduced brain oxidative metabolism in AD.
Oxidative Stress and Gene Mutations That Cause AD and the Genes Responsible for APP Processing
Gene mutations of APP and PS-1 that lead to FAD promote oxidative stress and/or reduced antioxidant defenses ( Table 2 ). Fibroblasts and lymphoblasts from FAD patients and frontal cortex of autopsy brains from FAD patients bearing APP and PS-1 mutations show elevated oxidative damage and decreased endogenous antioxidant capacity. 28, 135, 136 b-secretase (BACE-1) together with g-secretase liberates Ab from APP. 4, 137 The activity of BACE-1 increases in sporadic AD patients. 127, 138 Both BACE-1 mRNA and protein expression are elevated in vivo in the frontal cortex. 127 The pathways regulating BACE have not been fully characterized. Oxidative stress is proposed to be one of the cause of elevated expression of BACE in AD. 128, 139 Thus, one reasonable hypothesis is that oxidative stress elevates BACE which increases Ab production and that will further exaggerate oxidative stress. In addition, hypoxia also increases BACE-1 expression and Ab generation, and that is mediated by hypoxia-inducible factor-1a (HIF-1a). 140 
REDOX STATE AND GENE EXPRESSION IN CELLULAR OR ANIMAL MODELS OF AD
Growing evidence indicates that cellular reduction/ oxidation (redox) status regulates various aspects of cellular function including gene expression. Oxidative stress can elicit positive responses such as cellular proliferation or activation, and negative responses such as growth inhibition or cell death. As reviewed in the previous section, genes altered in autopsy brains of AD patients and genetic mutations that lead to AD seem to be associated with oxidative stress. Numerous cell and animal models of AD have been developed and considerable effort has been exerted to identify mechanisms of redox state-mediated gene regulation in relation to AD pathology. Only a fraction of the studies that are related to oxidative stress-regulated gene expression will be covered in this section to further support that oxidative stress regulates the expression of genes that are implicated in AD.
Stress Response and Antioxidant Genes
Elevated expression of stress and antioxidant defense genes occurs in AD and it is likely regulated by oxidative stress. H 2 O 2 or menadione induces HO-1 expression (mRNA and protein) followed by mitochondrial iron deposition in rat primary astrocytes. 141 HO-1 and Mn-Cu/Zn SOD are profoundly induced in aged AD transgenic mice and in PC-12 cells upon exposure of oxidative stress. 113, 116 CAT is also induced in cortical neurons and astrocytes after oxidative stress induced by the redox-cycling compound paraquat. 117 Age-related increases in oxidative stress induce GSH-Px in transgenic Tg2576 mice with AD-like pathology. 118 These findings provide further and direct evidence that oxidative stress is a mediator of the induction of stress and antioxidant gene expression in affected brain regions of AD.
Inflammatory Genes
Elevated expression of proinflammatory genes has been demonstrated in a numbers of neurodegenerative diseases, including AD and the changes could plausibly result from oxidative stress. Oxidative stress regulates induction of proinflammatory genes through activation of JNK, p38, and MAPK. 130 Induction of ROS in rat microglia and astrocytes by treatment of cells with lipopolysaccharide and IFN-g increases the expression of iNOS. 122 Moreover, primary astrocytes from NADPH oxidase-deficient mice have attenuated ROS production and diminished induction of iNOS in response to lipopolysaccharide/IFN-g. These findings suggest that NADPH oxidase-derived ROS are crucial for proinflammatory gene expression in glial cells. 122 Oxidative stress is associated with selective neuronal loss during thiamine deficiency (TD). 142 TD elevates expression of several inflammatory genes such as tumor necrosis factor-a, IL-1b, and IL-6 in submedial thalamic nucleus, the region most sensitive to TD and where oxidative stress is most profound. 120
Energy Metabolism Genes
Impaired energy metabolism occurs in a number of neurodegenerative diseases including AD. KGDHC can be a rate-limiting enzyme in the mitochondrial TCA cycle, a major oxidative energy pathway. Diminished KGDHC activity has been well documented in AD by several independent groups. Although a direct link between inactivation of KGDHC activity and various oxidants has been established in isolated enzymes, cell, and animal models, 63, 143, 144 whether oxidative stress regulates the gene expression of KGDHC has not been tested. Our studies on the gene expression of KGDHC in TD mice reveal a region and time-dependent profile. 124 Downregulated gene expression of the 3 subunits of KGDHC occurs in the submedial thalamic nucleus region where oxidative stress coexists with neuronal loss and microglial activation.
APP Processing Genes
b-Secretase (BACE-1) is the key rate-limiting enzyme for the generation of Ab peptide involved in the pathogenesis of AD. [145] [146] [147] Although the mechanism of regulating BACE is not fully understood, oxidative stress is one plausible factor responsible for elevated expression of BACE in AD. 127 In NT2 neurons, oxidative stress significantly increases expression and activity of BACE that leads to elevation of carboxy-terminal fragments of APP. 128 These cellular studies suggest that oxidative stress may be directly responsible for BACE activation and Ab production in AD.
This section on redox state and gene expression in cellular or animal models of AD provides evidence that oxidative stress modulates the expression of genes that are associated with AD. Although the effects of specific redox perturbations can be similar in many organisms and tissues, some of them are likely to be cell or tissuespecific. 148 For example, heterogeneity in c-Jun mRNA level occurs in a number of human fibroblast, leukemia, melanoma, sarcoma, and carcinoma cell types exposed to H 2 O 2 . 149 The expression of genes involved in JNK/ SAPK-c-Jun pathway is activated most strongly in astrocytes of amyotrophic lateral sclerosis patients, whereas motor neurons show unusually low expression of the pathway. 150 Thus, studies on cell, tissue, or region specific gene expression profile in response to oxidative stress would help to better understand the underlying mechanisms of tissue variations in AD.
REDOX-REGULATED TRANSCRIPTION FACTORS IN AD
ROS-mediated transcriptional regulation is relevant to altered gene expressions in AD. Several classic transcription factors, namely nuclear factor-kB (NF-kB), activator protein-1 (AP-1), specificity protein-1 (Sp-1), and HIF are known to modulate gene expression in response to cellular oxidative stress. These are summarized in Table 3 . Recently, great interest has increased in cofactors of transcription factors owing to their ability to modulate the activation or suppression of transcription factors. Peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a) is one of these coactivators that are particularly important for mitochondrial biogenesis.
NF-jB and AP-1
NF-kB, a redox-sensitive transcription factor, plays an important role in proinflammatory and protective pathways, including transcription of cytokine genes and antioxidant genes. 151, 152 In neurons, the most common NF-kB consists of p50, p65/RelA, and I-kB subunits. [153] [154] [155] [156] Normally, NF-kB resides in the cytoplasm as an inactive form bound with the inhibitory subunit I-kB. Upon stimuli such as oxidative stress, I-kB is phosphorylated and proteolysized, which leads to translocation of free NF-kB into the nucleus where it binds to promoter regions of its target genes. Age-related oxidative stress regulates the dissociation of I-kB and nuclear translocation of NF-kB. 157 Treatment of a human T-cell line with hydrogen peroxide rapidly activates NF-kB. 158 Stress response gene HO-1 exhibits several transcription factor binding sites, including NF-kB 114 and is elevated in brains of AD patients. In addition to several altered NF-kB target genes, increased activation of NF-kB also occurs in neurons and astrocytes associated with Ab plaques in brains of AD patients. 159 Thus, oxidative stress activates NF-kB that will elevate expression of inflammatory and antioxidant genes in AD. AP-1 is another transcription factor that is regulated by intracellular redox state. AP-1 is a dimeric transcription factor composed of the Jun and Fos gene families. AP-1 is induced by hydrogen peroxide, UV irradiation, depletion of intracellular glutathione by buthionine-(SR)-sulfoximine (BSO). 160 AP-1 activates transcription of genes involved in both proinflammatory and antioxidant pathways through phosphorylation of JNK pathway. For example, oxidative stress modulates HO-1, IL-8, and ICAM-1 gene transcription by activation of NF-kB and/or AP-1. [161] [162] [163] [164] Thus, AP-1 together with NF-kB regulate expression of a wide range of genes that are involved in inflammatory and antioxidant defense pathways associated with AD pathology.
Sp-1
Sp-1 is a redox-sensitive transcription factor and its DNA-binding activity is modulated by the cellular redox state. Sp-1 belongs to the zinc-finger family of DNAbinding proteins. It acts on transcription of both TATA-less and TATA-containing promoters. The DNA-binding activity of Sp-1 is decreased with age and the decline can be reversed by addition of high concentration of reducing agents. 165, 166 It has been shown that Sp-1 is essential for the constitutive expression of the human Mn-SOD gene. 167 p53 is a transcription regulator that suppresses tumor development. The expression of Mn-SOD is negatively regulated through the interaction of p53 with Sp-1. 168 Sp-1 is also likely to regulate genes that are involved in glucose metabolism such as the TCA cycle. Early studies on promoter analysis of DLST (gene encoding the E2k of KGDHC) and DLD (gene encoding the E3 of KGDHC) reveal a Sp-1 binding site in promoters of both genes. 169, 170 Similarly, MDH2 encoding one of the TCA cycle enzymes, malate dehydrogenase, shows a potential binding site for Sp-1. 171 However, further studies on gene regulations have not followed. Considering altered mRNA levels of KGDHC and MDH2 in brains of AD patients and an animal model of AD, future studies on transcriptional regulations of these genes would provide new insights into impaired energy metabolism in relation to AD pathology.
HIF-1a
The HIF is a master regulator of genes of oxygen homeostasis. HIF belongs to the large family of basichelix-loop-helix transcription factors. It binds DNA as a heterodimer of 1 oxygen-sensitive a-subunit (HIF-1a, HIF-2a, or HIF-3a) and 1 stable b-subunit (HIF-1b) (for review see Ref. 172) . Under normoxic conditions, prolylhydroxylase-domain proteins (PHDs) hydroxylate HIF-1a, which initiates the degradation of HIF-1a by the proteasome. Low oxygen levels decrease PHD activity and thus stabilize HIF-1a, which induces expression of a serial HIF target genes, including glycolysis-related genes (for review see Ref. 173) . Oxidative stress also regulates HIF stability. Incubation of cells with H 2 O 2 or other oxidative stressors leads to the stabilization of HIF-1a and activation of HIF target genes. [174] [175] [176] [177] HIF induces glycolysis-related genes including glucose-6-phosphate dehydrogenase and hexokinase 1, 2 (for review see Ref. 173) . A recent study demonstrates that HIF-1 suppresses energy metabolism through the TCA cycle by directly transactivating the gene encoding PDH kinase 1 (PDK1). 178 PDK1 inhibits the PDH complex, the enzyme that provides acetyl-CoA to initiate the TCA cycle. Thus, the ability of ROS to activate HIF leads to activation of the genes of glycolysis and to inhibition of PDH complex which together shunt glucose metabolism from the mitochondria to glycolysis. This provides cellular adaptation and protection in response to oxidative stress.
PHD requires O 2 , ferrous iron [Fe(II)], and a-ketoglutarate for full function. 179, 180 Thus, in addition to O 2 availability, changes in the other 2 cofactors would regulate PHD activity. Enhanced H 2 O 2 levels promote the oxidation of Fe(II) to Fe(III) and limit the availability of Fe(II) for activation of PHD and lead to stabilization of HIF. 181 The TCA cycle intermediates such as pyruvate 182 Thus, ROS and the TCA cycle intermediates are important modulators of PHD through acting on iron availability [181] [182] [183] [184] [185] and a-ketoglutarate binding. 184 Interestingly, both substrate (a-ketoglutarate) and product (succinate) of PHD are intermediates of the TCA cycle. Accumulation of succinate as a result of mutation in succinate dehydrogenase inhibits PHD and stabilizes HIF. 186 Thus, accumulation of the TCA cycle intermediates owing to inactivation of mitochondrial metabolic enzymes may represent both adaptive and protective response to oxidative stress associated with AD.
Peroxisome Proliferators-activated Receptor-c Coactivator-1a (PGC-1a)
The peroxisome proliferators-activated receptors (PPARs) are members of a nuclear receptor superfamily that regulates transcription of genes involved in lipid, cholesterol, lipoprotein metabolism, glucose energy metabolism, and immune response. The PPARg plays a critical role in regulating adipogenesis (for review see Refs. [187] [188] [189] . PGC-1a is a coactivator of PPARg, and is strongly expressed in brown adipose tissue, heart, skeletal muscle, kidney, and brain. [190] [191] [192] PGC-1a is a potent stimulator of mitochondrial biogenesis and respiration. 190, [193] [194] [195] [196] The expression of PGC-1a in 10T1/2 cells is increased significantly upon H 2 O 2 treatment. 197 H 2 O 2induced gene expression of the ROS defense system, including Cu/Zn-SOD (SOD1), Mn-SOD (SOD2), CAT, and GSH-Px is mediated by PGC-1a. 197 An increased sensitivity to oxidative stress in the brain of PGC-1a KO mice and protection of wild-type neural cells from oxidative stress through an increase in expression of ROS-detoxifying genes by PGC-1a supports an important role of PGC-1a in suppressing ROS and neurodegeneration.
A number of transcription factor targets of PGC-1a have been discovered (for review see Ref. 198) (Table 3) . NRF-1, NRF-2, PPARa, PPARb, ERRa, and TR are of particular interest because of their roles in regulating the expression of many nuclear-encoded mitochondrial genes such as cytochrome c, complex I to IV, and ATP synthase subunits (for review see Ref. 193, 199) . Moreover, PPARs regulate inflammatory reactions. 200 For example, PPARg inhibits the transcription of proinflammatory molecules such as iNOS without direct binding to the gene promoter, and such inhibition is achieved in part through antagonizing the activities of the transcription factors AP-1, STAT, and NF-kB. [201] [202] [203] Interactions of PGC-1a with other signal pathways may also be important in the response to oxidative stress and AD. Cre-binding protein (CREB) is an important regulator of PGC-1a expression under normal physiologic conditions and in response to oxidative stress. 197, 204, 205 Nitric oxide induces PGC-1a levels and triggers mitochondrial biogenesis through cGMP-dependent pathways. 206 p38-MAPK activates PGC-1a 207, 208 and PPARa. 209 It is a great challenge to understand the integration of these signalling pathways involved in mitochondrial function and biogenesis in response to oxidative stress.
TRANSCRIPTION FACTORS AS THERAPEUTIC TARGETS IN AD
Currently, medications available for the treatment of AD patients are cholinesterase inhibitors, including galantamine, donepezil, and rivastigmine, 126, [210] [211] [212] [213] and the NMDA-receptor antagonist, memantine. 214 As these drugs produce very moderate symptomatic benefits, the development of novel drugs with strong disease modifying properties is a great need today. Development of new drugs that will initiate endogenous cytoprotective properties is one of the attractive therapeutic strategies (Fig. 3 ).
Transcription factors
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Normal Cell Function interfere with binding to promoters of ''toxic genes'' and suppress transcription of cytotoxic genes that would block production of gene products leading to cell dysfunction (right section of the diagram). We hypothesize this strategy would be more effective than just trying to fix the cellular abnormalities that result from harmful gene expression. Acetyl-L-carnitine is proposed as a therapeutic agent for a number of neurodegenerative diseases. Treatment of senescent rats for 4 months with acetyl-L-carnitine induces HO-1, Hsp70, and SOD-2. Acetyl-L-carnitine also upregulates glutathione levels, prevents age-related changes in mitochondrial respiratory chain complex expression and reduces protein carbonyls and HNE formation. 215 As discussed above, PPARg belongs to nuclear receptor family and is a ligand-activated transcription factor. This unique feature makes it a valuable target for new drug developments. PPARg agonists are shown to be efficacious in animal models of AD through their antiinflammatory and neuroprotective effects (for review see Ref. 216 ). Long-term intake of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk for AD and delays onset and progression of the disease. 217, 218 PPARg is a potent target of some NSAIDs, 219, 220 and the induction of PPARg by NSAIDs reduces Ab levels in cell and animal models of AD. [221] [222] [223] The search of therapeutic strategies for AD has been recently expanded from targeting downstream pathways of amyloid cascade to upstream pathways that are associated with mitochondrial biogenesis. PGC-1a has been established as the master regulator of mitochondrial function and oxidative metabolism. PGC-1a naturally binds and responds to small lipophilic molecules. The search for both agonists and antagonists of PGC-1a will make it as an attractive therapeutic target. Down-regulated expression of PGC-1a has been implicated in Huntington disease (HD) and in several HD animal models. 224, 225 Cui et al 224 have reported that mutant huntingtin (htt) suppresses PGC-1a transcription by associating with the promoter and interfering with the CREB/TAF4-dependent pathway. Expression of PGC-1a in striatal neuronal progenitor cells expressing mutant htt protects against mitochondrial dysfunction induced by mutant htt. Delivery of PGC-1a by lentivirus in the striatum provides neuroprotection in the transgenic HD mice. 224 These studies provide evidence of an important role of PGC-1a in mitochondrial biogenesis. Thus, molecules that activate PGC-1a and lead to stimulation of energy metabolism pathways may be potentially beneficial for HD and possibly for AD in which impaired mitochondrial function and oxidative stress are implicated.
SUMMARY
Oxidative stress is an early event in AD that precedes the formation of AD pathologies. Although numerous effects have been made to develop therapies based on antioxidants in the past years, the actual benefits to the patients have been very limited. It is likely due to lack of potency, late administration, and poor penetration into the brain cells. Alternative strategies including searching for factors that initiate endogenous cytoprotection are necessary to improve the efficacy of treatment (Fig. 3) . ROS serve as subcellular messengers in gene regulation and signal transduction pathways, in addition to their deleterious effects on cellular biomolecules. Thus, understanding how oxidative stress modulates gene expressions that are critical to AD pathology might help to develop effective therapeutic strategies. This review summarized several aspects of oxidative stress and its relation to AD based on data collected from peripheral cells, AD autopsy brains, cellular, and animal models. Oxidative stress-induced alterations that are associated with AD, including impaired energy metabolism were discussed. In particular, the review highlighted current progress on the association of oxidative stress with altered gene expression and redox-sensitive transcription factors that might contribute to AD pathophysiology. Possible therapeutic strategies to target redox-sensitive transcription factors or their cofactors are suggested based on the updated view of redox-dependent gene regulation in AD.
